Title: Efficacy and Safety of Chemoradiation Therapy Using One- Shot Cisplatin via Hepatic
Arterial Infusion for Advanced Hepatocellular Carcinoma with Major Macrovascular Invasion:
a Single-arm Retrospective Cohort Study
Version: 1 Date: 23 Feb 2022
Reviewer's report:
This is a retrospective study reporting the effects of chemoradiation with one-shot CisPt HIA
for HCC with macrovascular invasion. This is a very interesting approach for these patients
who exhibit a very bad prognosis due to the vascular invasion. Nevertheless, there are many
limitations:
1) It is a retrospective study with a small population
2) The observation period is very long (16 years!). During this time, many improvements have
occurred in diagnosis and treatment
3) A major bias is the “over-selection” of patients evaluated in this study. Indeed, it is very rare
for HCC patients with major macrovascular invasion to have preserved liver function and PS 0/1
4) Response was assessed with mRECIST and not with RECIST 1.1. It is mandatory to have
the RECIST 1.1 assessment. The best ORR is 16% and therefore lower than expected results
with new systemic regimens with CPI
5) Description of adverse events is very poor: no information about leukopenia, renal
insufficiency,…
Based on these comments, we cannot draw clear conclusions about safety and efficacy of
chemoradiation and therefore cannot publish this work.
My suggestion for improve your study are:
1) Safety and feasibility should be the primary evaluation criteria. You must describe in more
detail the AEs and also describe the manner and the period of collection of these AEs
2) Response should also be evaluated with RECIST 1.1 The range for the median time of first
evaluation must be added
3) The type and time of initiation of additional systemic therapy should be defined
4) English should be improved
5) References in the text are not always adequate
Title: Efficacy and Safety of Chemoradiation Therapy Using One- Shot Cisplatin via Hepatic
Arterial Infusion for Advanced Hepatocellular Carcinoma with Major Macrovascular Invasion:
a Single-arm Retrospective Cohort Study
Version: 1 Date: 23 Feb 2022
Reviewer's report:
This is a retrospective study reporting the effects of chemoradiation with one-shot CisPt HIA
for HCC with macrovascular invasion. This is a very interesting approach for these patients
who exhibit a very bad prognosis due to the vascular invasion. Nevertheless, there are many
limitations:
1) It is a retrospective study with a small population
2) The observation period is very long (16 years!). During this time, many improvements have
occurred in diagnosis and treatment
3) A major bias is the “over-selection” of patients evaluated in this study. Indeed, it is very rare
for HCC patients with major macrovascular invasion to have preserved liver function and PS 0/1
4) Response was assessed with mRECIST and not with RECIST 1.1. It is mandatory to have
the RECIST 1.1 assessment. The best ORR is 16% and therefore lower than expected results
with new systemic regimens with CPI
5) Description of adverse events is very poor: no information about leukopenia, renal
insufficiency,…
Based on these comments, we cannot draw clear conclusions about safety and efficacy of
chemoradiation and therefore cannot publish this work.
My suggestion for improve your study are:
1) Safety and feasibility should be the primary evaluation criteria. You must describe in more
detail the AEs and also describe the manner and the period of collection of these AEs
2) Response should also be evaluated with RECIST 1.1 The range for the median time of first
evaluation must be added
3) The type and time of initiation of additional systemic therapy should be defined
4) English should be improved
5) References in the text are not always adequate
Please review this paper.
user
Title: Efficacy and Safety of Chemoradiation Therapy Using One- Shot Cisplatin via Hepatic
Arterial Infusion for Advanced Hepatocellular Carcinoma with Major Macrovascular Invasion:
a Single-arm Retrospective Cohort Study
Version: 1 Date: 23 Feb 2022
Reviewer's report:
This is a retrospective study reporting the effects of chemoradiation with one-shot CisPt HIA
for HCC with macrovascular invasion. This is a very interesting approach for these patients
who exhibit a very bad prognosis due to the vascular invasion. Nevertheless, there are many
limitations:
1) It is a retrospective study with a small population
2) The observation period is very long (16 years!). During this time, many improvements have
occurred in diagnosis and treatment
3) A major bias is the “over-selection” of patients evaluated in this study. Indeed, it is very rare
for HCC patients with major macrovascular invasion to have preserved liver function and PS 0/1
4) Response was assessed with mRECIST and not with RECIST 1.1. It is mandatory to have
the RECIST 1.1 assessment. The best ORR is 16% and therefore lower than expected results
with new systemic regimens with CPI
5) Description of adverse events is very poor: no information about leukopenia, renal
insufficiency,…
Based on these comments, we cannot draw clear conclusions about safety and efficacy of
chemoradiation and therefore cannot publish this work.
My suggestion for improve your study are:
1) Safety and feasibility should be the primary evaluation criteria. You must describe in more
detail the AEs and also describe the manner and the period of collection of these AEs
2) Response should also be evaluated with RECIST 1.1 The range for the median time of first
evaluation must be added
3) The type and time of initiation of additional systemic therapy should be defined
4) English should be improved
5) References in the text are not always adequate
assistant